| P2093 | author name string | N Vuilleumier | |
| | P Cutler | |
| | P C Teixeira | |
| P2860 | cites work | Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity | Q84529188 |
| | High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage | Q85560889 |
| | Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. | Q51503137 |
| | Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. | Q51590860 |
| | Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. | Q52537589 |
| | Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability | Q58197642 |
| | Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis | Q58197651 |
| | Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q79267289 |
| | The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies | Q79326313 |
| | Oxidative stress influences CC-chemokine levels in hemodialyzed patients | Q80038246 |
| | Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome | Q80220505 |
| | Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease | Q81078144 |
| | Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease | Q81537671 |
| | Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques | Q81926367 |
| | Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies | Q83433656 |
| | Accelerated atherosclerosis in patients with SLE--mechanisms and management | Q26820245 |
| | Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? | Q33345061 |
| | Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction | Q33533540 |
| | Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states | Q33802371 |
| | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment | Q33943374 |
| | Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels | Q34130086 |
| | Autoimmune‐mediated reduction of high‐density lipoprotein–cholesterol and paraoxonase 1 activity in systemic lupus erythematosus–prone gld mice | Q34546651 |
| | High density lipoprotein: it's not just about lipid transport anymore | Q34565254 |
| | Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial | Q34817084 |
| | Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures | Q35768215 |
| | Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease | Q36037988 |
| | Plaque rupture in humans and mice | Q36749108 |
| | Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction | Q37045449 |
| | Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis | Q37173216 |
| | Characteristics and causes of immune dysfunction related to uremia and dialysis. | Q37190764 |
| | Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases | Q37192860 |
| | The autoimmune origin of atherosclerosis | Q37202020 |
| | The metabolism and anti-atherogenic properties of HDL. | Q37334590 |
| | Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors | Q37425906 |
| | HDL metabolism and activity in chronic kidney disease | Q37716581 |
| | Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases | Q37824302 |
| | Impact of coronary artery calcification in hemodialysis patients: Risk factors and associations with prognosis | Q39888519 |
| | Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors | Q40315752 |
| | Serum amyloid A (SAA): an acute phase protein and apolipoprotein | Q40384379 |
| | High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome | Q43197413 |
| | Early diagnosis of myocardial infarction with sensitive cardiac troponin assays | Q43285257 |
| | Heart rate and cardiovascular mortality: the Framingham Study | Q43463488 |
| | Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. | Q43613628 |
| | Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? | Q43832641 |
| | Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome | Q44183283 |
| | Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. | Q44429511 |
| | Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. | Q45956369 |
| | Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus | Q46982870 |
| | Prevalence of conventional risk factors in patients with coronary heart disease | Q47677468 |
| | Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. | Q47719633 |
| | Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex | Q50253399 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | lipid | Q11367 |
| | immunoglobulin G | Q79448 |
| | cardiovascular disease | Q389735 |
| | autoantibody | Q785022 |
| | Apolipoprotein A1 | Q1316030 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 868251 | |
| P577 | publication date | 2012-11-20 | |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives | |
| P478 | volume | 2012 | |